drugset
Drugs / m-IPV HD
last change Dec 2015 re-read 3 minutes ago

m-IPV HD

also known as mIPV2HD · monovalent high-dose inactivated poliovirus type 2 vaccine

Vaccine

Developed for
poliomyelitis
Investigated by
Bill and Melinda Gates Foundation · Vaxtrials S.A.

Trials 1

today NCT02111135 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02111135 Apr → Sep 2014 poliomyelitis Vaxtrials S.A. Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as m-IPV HD ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111135 ↗
Known as mIPV2HD “We assessed the immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine (mIPV2HD) in infants.” PMID 26719058 ↗ Dec 2015
1

“monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)” NCT02111135 ↗
Known as monovalent high-dose inactivated poliovirus type 2 vaccine “monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)” NCT02111135 ↗
Modality Vaccine “monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)” NCT02111135 ↗